A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-105 in Patients With Advanced Solid Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
研究概览
简要总结
Open-label, non-randomized, Phase I, dose-escalating, first-in-man study.
详细描述
The study consisted of a screening period, a treatment period with repeated 28-day treatment cycles (duration treatment with ICP-105), and a follow-up period (within 30 days of the last dose and post-treatment follow-up 30 days after the last visit). The recruited patients receive a single dose on day 1, then after a 3-day washout period, multiple dosing will be initiated following dose-escalation schedule. The dose-limiting toxicity (DLT) assessment period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (28-day cycle).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 Years and older.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •At least one evaluable disease according to RECIST1.
- •Histologically or cytologically confirmed solid tumors, failure to respond to standard therapy, or for whom standard therapy does not exist.
- •Adequate bone marrow, liver, renal, and cardiovascular function.
排除标准
- •Previous treatment with FGF19, FGFR4 inhibitors and/or pan-FGFR inhibitors.
- •Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-
- •Major surgery within 6 weeks of the first dose of ICP-
- •Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-
- •Crohn's disease with symptoms and systemic treatment.
- •Central nervous system (CNS) metastasis.
- •Current clinically significant cardiovascular disease including:
- •Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male).
- •Known active bleeding within 2 months of screening or 6 months of bleeding history.
- •Lung function impairment by pleural effusion or ascites, any history of interstitial pneumonia, deep vein thrombosis, pulmonary embolism.
- •Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection.
- •Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy (excluding alopecia, nausea and vomiting).
- •Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children.
研究组 & 干预措施
ICP-105 Single Arm
ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
干预措施: ICP-105 (Drug)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
时间窗: Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study
will be evaluated by CTCAE v4.03
次要结局
- AUC(Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study)
- Cmax(Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study)
- Apparent half-life for designated elimination phases (t½)(Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study)